Palvella Therapeutics Inc.

01/10/2025 | Press release | Distributed by Public on 01/10/2025 07:02

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.